Analyst Ratings For CVS Health
Portfolio Pulse from Benzinga Insights
Analyst ratings for CVS Health (NYSE:CVS) over the last three months show a mix of opinions, with a recent shift towards a somewhat bullish outlook. The average 12-month price target has been adjusted to $86.33, a decrease from the previous $89.50. Analysts from firms like Cantor Fitzgerald, Piper Sandler, Barclays, Leerink Partners, and RBC Capital have provided updates, with actions ranging from maintaining to raising or lowering their ratings and price targets. CVS Health's financial performance indicates strong market position, revenue growth, and profitability, with a market capitalization that asserts its dominance in the healthcare sector.
April 04, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analyst ratings for CVS Health have shown a somewhat bullish trend with a new average 12-month price target set at $86.33, down from $89.50. Financial indicators suggest a strong market position and profitability, with significant revenue growth and effective debt management.
The somewhat bullish outlook from analysts, combined with CVS Health's strong financial performance and market position, suggests a positive short-term impact on the stock. The adjustment in the average price target reflects a nuanced view of the company's future performance, but the overall positive financial health and strategic acquisitions like Oak Street indicate potential for growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100